Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease
Launched by APOGENIX GMBH · Dec 3, 2022
Trial Information
Current as of January 17, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol
- • ≥18 years of age
- • Patient is admitted to a hospital (max. 72 hours prior to randomization) due to COVID-19 and has a positive SARS-CoV-2 PCR test
- • Clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the WHO 10-point clinical progression scale) with COVID 19 prior to trial treatment
- • Patient agrees to not participate in another clinical trial from screening until day 56
- Exclusion Criteria:
- • Patient is moribund or has an estimated life expectancy \<1 month (e.g., terminal cancer, etc.)
- • Patient is anticipated to be discharged from hospital within 48 hours
- • Patient requires anti-inflammatory medicines beyond SoC (SoC are drugs that are approved for treatment of COVID-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization)
- • Patient requires invasive mechanical ventilation
- • Patient is known to have active tuberculosis
- • Patient is known to have hereditary fructose intolerance.
- • Patient is known to have co-infection with Influenza viruses or other viral respiratory infections (respiratory syncytial virus \[RSV\], parainfluenza viruses, respiratory adenoviruses).
Trial Officials
Eike C. Buss, MD
Study Chair
Apogenix AG
About Apogenix Gmbh
Apogenix GmbH is a biopharmaceutical company focused on developing innovative therapeutic solutions for cancer and other serious diseases. With a strong emphasis on harnessing the power of the immune system, Apogenix is advancing its proprietary platform of drug candidates designed to target and modulate immune responses. The company is dedicated to conducting rigorous clinical trials to evaluate the safety and efficacy of its therapies, aiming to improve patient outcomes and quality of life. Committed to scientific excellence and collaboration, Apogenix strives to bring transformative treatments from the lab to the clinic.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, , Germany
Barcelona, , Spain
Valladolid, , Spain
Limoges, , France
Paris, , France
Benoni, , South Africa
Johannesburg, , South Africa
Mysore, Karnataka, India
Madrid, , Spain
Milan, , Italy
Salamanca, , Spain
Milano, , Italy
Wien, , Austria
Amiens, , France
Kutaisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Köln, , Germany
Visakhapatnam, Andrha Pradesh, India
Bangalore, Karnataka, India
Pune, Maharashta, India
Aurangabad, Maharashtra, India
Pune, Maharashtra, India
Lucknow, Uttar Pradesh, India
Bangalore, , India
Nehru Nagar, , India
Sūrat, , India
Napoli, , Italy
Napoli, , Italy
Bolesławiec, , Poland
Koszalin, , Poland
Wrocław, , Poland
Three Rivers, , South Africa
Alicante, , Spain
Vigo, , Spain
Brive La Gaillarde, , France
Ulhasnagar, Maharashtra, India
Pretoria, Gauteng, South Africa
Durban, , South Africa
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials